VJHemOnc is committed to improving our service to you

COSTEM 2019 | Is MRD monitoring prior to allograft standard in AML?

VJHemOnc is committed to improving our service to you

Michael Heuser

Michael Heuser, MD, Hannover Medical School, Hannover, Germany, talks on standard practice and measurable residual disease (MRD) monitoring prior to allograft in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter